SOURCE: TNI BioTech, Inc.

October 11, 2012 07:30 ET

Dr. Henry "Skip" Lenz, Pharm.D, Joins TNI BioTech, Inc., as Quality Control Officer

NEW YORK, NY and POTOMAC MD--(Marketwire - Oct 11, 2012) - TNI BioTech, Inc. (PINKSHEETS: TNIB), a public company operating in the biotech sector, announced today the signing of an agreement with Pharmaceutical Care Consultants of South Florida, d/b/a Skip's Pharmacy. Under the agreement, Dr. Henry "Skip" Lenz and Phil Giordano will join the company as heads of Quality Control and Quality Assurance for TNIB's pharmaceutical plant in Managua, Nicaragua. Dr. Lenz will be responsible for leading the company's global manufacturing development.

Dr. Lenz will join the company's executive leadership team, and report to Noreen Griffin, CEO and Dr. Eugene Youkilis, President of TNI BioTech, Inc. As the company's Quality Control Officer, Dr. Lenz will be responsible for assuring all manufacturing meets cGMP standards. Dr. Lenz has held senior management positions in quality control, quality assurance and production for several international manufacturers. In addition, Dr. Lenz held senior clinical research pharmacist positions with both domestic and international clinical research groups, including Senior Researcher at Key Pharmaceuticals in charge of the Research Division. Dr. Lenz founded and ran a contract research company producing over 10 patents before being acquired by a mid-sized manufacturing company. Over the last fifteen years Dr. Lenz has set his sights on relieving HIV/AIDS by participating in clinical applications of several novel therapies.

Dr. Lenz is a graduate of The Massachusetts College of Pharmacy and the University of Florida. Currently, he owns Pharmaceutical Care Consultants of South Florida d/b/a Skip's Pharmacy in Boca Raton, Florida with his partner Phil Giordano. Skip's Pharmacy is dedicated to providing the highest quality and optimum pharmaceutical care through its unique ability to formulate and compound drugs specifically to meet patient's needs. Skip's Pharmacy has been the leading outlet for the supply of LDN for over ten years.

Noreen Griffin, TNI BioTech, Inc.'s CEO, noted the company's hiring of Dr. Lenz and his partners continues to reflect TNI BioTech's commitment to deliver a quality product and to become a world-class leader in innovative therapeutics for patients afflicted with autoimmune and infectious diseases such as cancer and HIV/AIDS.

Dr. Lenz stated, "I was pleased to see that TNIB was taking the manufacturing and distribution of IRT-103 (LDN) seriously. It is important that IRT-103 (LDN), a treatment that has done so much good for some any people, be available at a quality and a price that benefits everyone."

About TNI Biotech, Inc.

TNI BioTech, Inc., is a biotech company combating fatal diseases through the activation and mobilization of the body's immune system using our patented immunotherapy. Our products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.

Our proprietary technology, therapies and patents, will be used to treat a wide range of cancers. Our most advanced clinical programs involve immunotherapy that works by isolating a patient's lymphocytes and then incubating them together with Methionine Enkephalin (MENK) in an enriching external incubation system. After incubation the patient's lymphocytes are re-infused back into the patient where they combat and destroy tumor cells.

Even though Management considers any condition that results in altered-immune response a target for investigation, the Company will most likely pursue additional investigations for MENK as a valuable candidate in the treatment of the following:

  • Autoimmune states such as rheumatoid arthritis and multiple sclerosis;
  • As an adjunct to antibiotics in the treatment of infectious diseases;
  • In cancer patients undergoing chemotherapy, radiation treatments or surgery;
  • Patients with AIDS, in combination with retroviral drug therapy; and
  • In wound healing or herpes viral infections.

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release includes various "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which represent the Company's expectations or beliefs concerning future events. Statements containing expressions such as "believes," "anticipates," "intends," or "expects," used in the Company's press releases and in Disclosure Statements and Reports filed with the Over The Counter Markets through the OTC Disclosure and News Service are intended to identify forward-looking statements. All forward-looking statements involve risks and uncertainties. Although the Company believes its expectations are based upon reasonable assumptions within the bounds of its knowledge of its business and operations, there can be no assurances that actual results will not differ materially from expected results. The Company cautions that these and similar statements included in this report are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date thereof. The Company undertakes no obligation to publicly release any revisions to such forward-looking statements to reflect events or circumstances after the date hereof.

See for more information.

Contact Information

  • Contact:

    Global Investment Media

    Phone: 310-353-6277